Skip to main content
. Author manuscript; available in PMC: 2019 Dec 5.
Published in final edited form as: Cell Rep. 2019 Nov 26;29(9):2556–2564.e3. doi: 10.1016/j.celrep.2019.10.092

Figure 1. PD-1 Blockade at the Peak of Viremia Enhances CD8 T Cell Activation with No Immediate Impact on Viral Control.

Figure 1.

(A) Survival LCMV-c13-infected B6 mice following anti-PD-L1 treatment. n = 25 (control), n = 6 (days 0–8), and n = 30 (days 8–22) pooled from 3 experiments.

(B) Survival of LCMV-c13-infected B6 mice after adoptive transfer of unexhausted LCMV-specific CD8 T cells and treatment with anti-PD-L1 or isotype control. Data are from 3 experiments.

(C) Expression of CD4, CD8, CD44, and LCMV-gp276-specific T cell receptor (TCR) in peripheral blood mononuclear cells (PBMCs) from control and anti-PD-L1-treated mice on 14 dpi with LCMV-c13 infection. Representative plots are shown with mean ± SD from 3 experiments.

(D and E) Expression of CD4, CD8, CD44, PD-1, LAG-3, and LCMV-gp33-specific TCR in PBMCs on 22 dpi. Representative plots (D) and mean ± SD from 2 experiments (E) are shown.

(F) Plasma viral RNA load in LCMV-c13-infected mice on 22 dpi. Data pooled from 5 experiments are shown with median. The statistical difference was tested by the Mann-Whitney U test.

See also Figure S1.